Financials
Financial year 2025
Worth noting
- Figures corrected afterwards (2021).
Revenue
€ 31.3 million
▲ 7% vs 2024
Profit
Healthy€ 197,513
▼ 40% vs 2024
Debts
Normal€ 4.7 million
▼ 30% vs 2024
Orifarm Healthcare from Zaventem, company number BE0755731948, closed financial year 2025 with a result of € 197,513 after tax. For that financial year Orifarm Healthcare recorded revenue of € 31.3 million and equity of € 1.7 million. Compared with financial year 2024, the result moved from € 327,032 to € 197,513. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.
What happened at Orifarm Healthcare?
What happened at Orifarm Healthcare in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 197,513 (▼ 40% vs 2024). Source: NBB ↗
- Nicki Lund Kristensen became a director. NBB
- Mads Fink Eriksen became a director. NBB
- Thomas Brandhof became a director. NBB
- New establishment in Zaventem. KBO
- Hans Carl Boegh-Soerensen became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 485,559 profit in 2021 to € 197,513 profit in 2025.
Paid € 801,331 in corporate taxes since 2021.
Best year ever: 2021, with € 485,559 profit.
On average € 197,900 of value added per employee in 2023.
A new publication or filing at Orifarm Healthcare? We notify you, reason included.
Follow Orifarm HealthcareNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind Orifarm Healthcare are Thomas Brandhof, Nicki Lund Kristensen, Mads Fink Eriksen and Hans Carl Boegh-Soerensen. The shares are held by Orifarm Generics A/S B.O (100%).
Directors
According to the 2025 annual accounts
since 2024
since 2025
since 2025
since 2020
Shareholders
Orifarm Generics A/S B.O
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Da Vincilaan 7
1930 Zaventem
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 7 companies are registered at this address.
IQVIA Solutions Belgium
€ 33.1 million revenue · 2025
TAKEDA BELGIUM
€ 201.4 million revenue · 2025
IQVIA RDS & INTEGRATED SERVICES BELGIUM
€ 45.6 million revenue · 2025
IM ASSOCIATES
€ 3.1 million gross margin · 2025
IQVIA Cancer Research
€ 50,247 gross margin · 2025
+2 more
Details
- Company number
- 0755.731.948
- VAT number
- BE 0755.731.948
- Registered office
- Da Vincilaan 7, 1930 Zaventem
- Names & denominations
- Orifarm Healthcare
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 6 October 2020
- Peppol
- Active · Active since 11 Jun 2026
- Activities · NACE
Groothandel in farmaceutische en medische artikelen